Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D10GPJ
|
|||
| Drug Name |
STRO-002
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | |
| Company |
Sutro Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Folate receptor alpha (FOLR1) | Target Info | . | [2] |
| KEGG Pathway | Endocytosis | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| Cargo concentration in the ER | ||||
| WikiPathways | Folate Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03748186) Study of STRO-002, an Anti-Folate Receptor Alpha (FolRalpha) Antibody Drug Conjugate in Ovarian & Endometrial Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sutro Biopharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.